Immuno-Histochemical Analysis of PDGFRβ in OSCC: Clinical Significance and Prospects for Targeted Therapy: Immuno-Histochemical Analysis of PDGFRβ in OSCC: Clinical Significance

Sarah Rabbani; Aman ur Rehman; Rabia Anjum; Nauman Rauf Khan; Saima Chudhary

doi:10.54393/pjhs.v5i11.1927

Authors

Sarah Rabbani Department of Oral Pathology, University of Health Sciences, Lahore, Pakistan
Aman ur Rehman Department of Oral Pathology, Shaikh Zayed Postgraduate Medical Institute, Lahore, Pakistan
Rabia Anjum Department of Oral Pathology, University of Health Sciences, Lahore, Pakistan
Nauman Rauf Khan Department of Oral Pathology, University of Health Sciences, Lahore, Pakistan
Saima Chudhary Department of Oral Pathology, The University of Lahore, Lahore, Pakistan

DOI:

https://doi.org/10.54393/pjhs.v5i11.1927

Keywords:

Platelet-derived Growth Factor Receptor Beta, Squamous Cell Carcinoma, Immunohistochemistry, Clinical Significance

Abstract

The most prominent and key cells in cancer development are fibroblasts, known as cancer-associated fibroblasts. Limited data available on Head and Neck Cancer showed the presence of platelet-derived growth factor receptor beta as the most prevalent marker. Furthermore, therapies can be targeted against this receptor for the treatment of cancer. Objectives: To evaluate the expression of Platelet-derived growth factor receptor beta as a specific marker of cancer-associated fibroblasts in different grades of oral squamous cell carcinoma through immunohistochemistry. Methods: This descriptive study included 51 cases of squamous cell carcinoma of the head and neck region. Platelet-derived growth factor receptor beta expression was assessed based on the extent and intensity of immune-labelling in a tumor. SPSS was used to determine the association between the grade of tumor and Platelet-derived growth factor receptor beta expression. Results: Mean age was found as 53.65 + 17.15 years and there were 30 (58.8%) male and 21 (41.2%) female. The most commonly affected sites were glottis and supra-glottis areas accounting for 18.9% of total cases followed by the tongue which accounts for 13.2% of cases. The majority of the patients 34 (66.7%) patients had an intermediate grade of squamous cell carcinoma. In most cases, the degree of staining was strongest, with intermediate-grade tumors exhibiting the highest platelet-derived growth factor receptor beta staining. Conclusions: It was concluded that platelet-derived growth factor receptor beta emerges as a promising tumor marker in head and

References

Kawaharada M, Yamazaki M, Maruyama S, Abé T, Chan NN, Kitano T et al. Novel Cytological Model for the Identification of Early Oral Cancer Diagnostic Markers: The Carcinoma Sequence Model. Oncology Letters. 2022 Mar; 23(3): 1-9. doi: 10.3892/ol.2022.13196.

Mummudi N, Agarwal JP, Chatterjee S, Mallick I, Ghosh-Laskar S. Oral Cavity Cancer in the Indian Subcontinent–Challenges and Opportunities. Clinical Oncology. 2019 Aug; 31(8): 520-8. doi: 10.1016/j.clon.2019.05.013.

Xie L and Shang Z. Burden of Oral Cancer in Asia from 1990 to 2019: Estimates from the Global Burden of Disease 2019 study. PLoS One. 2022 Mar; 17(3): e0265950. doi: 10.1371/journal.pone.0265950.

Capote-Moreno A, Brabyn P, Muñoz-Guerra MF, Sastre-Pérez J, Escorial-Hernandez V, Rodríguez-Campo FJ et al. Oral Squamous Cell Carcinoma: Epidemiological Study and Risk Factor Assessment Based on A 39-Year Series. International Journal of Oral and Maxillofacial Surgery. 2020 Dec; 49(12): 1525-34. doi: 10.1016/j.ijom.2020.03.009.

Carvallo SL. Prognostic Value of Immuno-expression of CCR4, CCR5, CCR7 and CXCR4 in Squamous Cell Carcinoma of Tongue and Floor of the Mouth. Medicina Oral, Patologia Oral, Cirugia Bucal. 2019 May; 24 (3): e354-63. doi: 10.4317/medoral.22904.

Kilvaer TK, Rakaee M, Hellevik T, Vik J, Petris LD, Donnem T et al. Differential Prognostic Impact of Platelet-Derived Growth Factor Receptor Expression in NSCLC. Scientific Reports. 2019 Jul; 9(1): 10163. doi: 10.1038/s41598-019-46510-3.

Zhang H, Sun JD, Yan LJ, Zhao XP. PDGF-D/PDGFRβ Promotes Tongue Squamous Carcinoma Cell (TSCC) Progression Via Activating p38/AKT/ERK/EMT Signal Pathway. Biochemical and Biophysical Research Communications. 2016 Sep; 478(2): 845-51. doi: 10.1016/j.bbrc.2016.08.035.

Do Valle IB, Oliveira SR, Da Silva JM, Peterle GT, Có AC, Sousa-Neto SS et al. The Participation of Tumor residing pericytes in oral squamous cell carcinoma. Scientific Reports. 2023 Apr; 13(1): 5460. doi: 10.1038/s41598-023-32528-1.

Tsioumpekou M, Cunha SI, Ma H, Åhgren A, Cedervall J, Olsson AK et al. Specific Targeting of PDGFRβ in the Stroma Inhibits Growth and Angiogenesis in Tumors with High PDGF-BB Expression. Theranostics. 2020; 10(3): 1122. doi: 10.7150/thno.37851.

Thamilselvan S, Pandiar D, Krishnan RP, Ramalingam K, Pavithran P. Comparison of Broder’s and Bryne’s Grading System for Oral Squamous Cell Carcinoma with Lymph Node Metastases and Prognosis: A Scoping Review. Cureus. 2024 Jan; 16(1). doi: 10.7759/cureus.51713.

Kwon KY, Ro JY, Singhal N, Killen DE, Sienko A, Allen TC et al. MUC4 Expression in Non–Small Cell Lung Carcinomas: Relationship to Tumor Histology and Patient Survival. Archives of Pathology and Laboratory Medicine. 2007 Apr; 131(4): 593-8. doi: 10.5858/2007-131-593-MEINCL.

Shinohara ET, Gonzalez A, Massion PP, Olson SJ, Albert JM, Shyr Y et al. PDGFR-Β Expression in Small Cell Lung Cancer Patients. International Journal of Radiation Oncology* Biology* Physics. 2007 Feb; 67(2): 431-7. doi: 10.1016/j.ijrobp.2006.08.060.

Coursier D, Calvo F. CAFs vs. TECs: When Blood Feuds Fuel Cancer Progression, Dissemination and Therapeutic Resistance. Cellular Oncology. 2024 Mar; 47: 1-22. doi: 10.1007/s13402-024-00931-z.

Ebrahimi N, Fardi E, Ghaderi H, Palizdar S, Khorram R, Vafadar R et al. Receptor Tyrosine Kinase Inhibitors in Cancer. Cellular and Molecular Life Sciences. 2023 Apr; 80(4): 104. doi: 10.1007/s00018-023-04729-4.

Nurmik M, Ullmann P, Rodriguez F, Haan S, Letellier E. In Search of Definitions: Cancer‐Associated Fibroblasts and Their Markers. International Journal of Cancer. 2020 Feb; 146(4): 895-905. doi: 10.1002/ijc.32193.

Lin LH, Lin JS, Yang CC, Cheng HW, Chang KW, Liu CJ. Overexpression of Platelet-Derived Growth Factor and Its Receptor Are Correlated with Oral Tumorigenesis and Poor Prognosis in Oral Squamous Cell Carcinoma. International Journal of Molecular Sciences. 2020 Mar; 21(7): 2360. doi: 10.3390/ijms21072360.

Wang L, Song H, Yang S. The Expression Tendency and Prognostic Value of PDGFRΒ in Oral Cancer. doi: 10.21203/rs.3.rs-53698/v1.

Kartha VK, Stawski L, Han R, Haines P, Gallagher G, Noonan V et al. PDGFRβ is a Novel Marker of Stromal Activation in Oral Squamous Cell Carcinomas. PLoS One. 2016 Apr; 11(4): e0154645. doi: 10.1371/journal.pone.0154645.

Paulsson J, Sjöblom T, Micke P, Pontén F, Landberg G, Heldin CH et al. Prognostic Significance of Stromal Platelet-Derived Growth Factor Β-Receptor Expression in Human Breast Cancer. The American Journal of Pathology. 2009 Jul; 175(1): 334-41. doi: 10.2353/ajpath.2009.081030.

Piccin A, Di Pierro AM, Canzian L, Primerano M, Corvetta D, Negri G et al. Platelet Gel: A New Therapeutic Tool with Great Potential. Blood Transfusion. 2017 Jul; 15(4): 333. doi: 10.2450/2016.0038-16.

He Q, Kong L, Shi W, Ma D, Liu K, Yang S et al. Ezetimibe Inhibits Triple-Negative Breast Cancer Proliferation and Promotes Cell Cycle Arrest by Targeting the PDGFR/AKT Pathway. Heliyon. 2023 Nov; 9(11). doi: 10.1016/j.heliyon.2023.e21343.

Roskoski Jr R. The Role of Small Molecule Platelet-Derived Growth Factor Receptor (PDGFR) Inhibitors in the Treatment of Neoplastic Disorders. Pharmacological Research. 2018 Mar; 129: 65-83. doi: 10.1016/j.phrs.2018.01.021.